secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-04-14T23:59:59+00:00
Accession:  0001564590-22-014494
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.0, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara cuts 83% of workforce, ends all pipeline programs, reviews strategic options
--------------------------------------------------------------------------------

- Workforce reduction of ~83% leaves only 6 full-time employees; substantially complete by Q2 2022.
- Discontinues tovinontrine (IMR-687) in sickle cell, beta-thalassemia, and heart failure with preserved ejection fraction.
- Also discontinues development of IMR-261; company starts comprehensive strategic review to maximize shareholder value.
- One-time restructuring charge of $2.0-2.2 million expected in Q2 2022 for severance and benefits.
- Chief Medical Officer Kenneth Attie, M.D. departs effective April 20, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/0001564590-22-014494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000156459022014494/imra-8k_20220405.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-014494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer